Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

Overview of attention for article published in New England Journal of Medicine, May 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 74 news outlets
blogs: 2 blogs
twitter: 39 X users
patent: 6 patents

facebook: 3 Facebook pages
wikipedia: 1 Wikipedia page
googleplus: 1 Google+ user
guideline: 5 clinical guideline sources

Readers on

mendeley: 378 Mendeley

So far, Altmetric has seen 42 X posts from 39 X users, with an upper bound of 1,223,554 followers.

@geteccu @MondayNightIBD @abbvie @FerringUSA @JanssenUS Cuál es vuestra experiencia con Ozanimod? @DCharabaty @bastida_dr @DCebSan @maria_chs https://t.co/zs7Z8HqHDY

RT @Best_IBD_Papers: Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. https://t.co/XPCzfY6VsM

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. https://t.co/XPCzfY6VsM

Ozanimod $RCPT $CELG Induction and Maintenance Treatment for Ulcerative Colitis — NEJM. I Don't agree w/ conclusion https://t.co/XYIoWaXx96

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 38 additional X posts.